

November 25, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the additional indication of Olaparib film-coated Tablets 100 mg & 150 mg (Lynparza).

Through this approval, Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer whose disease has not progressed on first-line treatment with Durvalumab in combination with platinum-based chemotherapy.

The receipt of this permission paves way for the launch of Olaparib film-coated Tablets 100 mg & 150 mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you
Yours faithfully

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary